SCHEMBL9908372

SCHEMBL9908372

CCNC(=O)c1ccc(CC)cn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.53
MAPT P10636 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
CNR1 P21554 1/20 0.46
HIF1A Q16665 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
PKM P14618 1/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
NFKB1 P19838 1/20 0.45
THPO P40225 1/20 0.45
BLM P54132 1/20 0.45
PMP22 Q01453 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12561176 0.84 PLK1 (0.55) PARP1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL25737802 0.83 LOXL2 (0.50) PARP1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL11629400 0.83 PARP1 (0.54) PARP1MAPTNPC1HIF1AKDM4E
SCHEMBL27308715 0.83 MAPT (0.49) PARP1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL18373773 0.82 HDAC6 (0.52) PARP1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL12315017 0.82 SMN1; SMN2 (0.61) SMN1; SMN2NPC1RAB9AHIF1AALDH1A1
SCHEMBL9561524 0.81 ALDH1A1 (0.51) SMN1; SMN2NPC1RAB9ACNR1KDM4E
SCHEMBL1976949 0.81 CNR1 (0.47) PARP1CNR1KDM4ELMNAL3MBTL1
SCHEMBL10228354 0.81 CNR1 (0.57) PARP1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL14959680 0.81 ALDH1A1 (0.53) SMN1; SMN2NPC1RAB9AKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023109521-A1 PARP INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF 凯复(苏州)生物医药有限公司 2023-06-22 WO disclosed
EP-2686321-B1 PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES BRISTOL MYERS SQUIBB CO (US) 2016-11-16 EP disclosed
US-8198273-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2012-06-12 US disclosed
US-20100286142-A1 Compounds and Methods for Kinase Modulation, and Indications Therefor PLEXXIKON, INC. 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286142-A1 Compounds and Methods for Kinase Modulation, and Indications Therefor BRAF, ARAF, RAF1 PARP1 2626/4885MAPT 3038/4885SMN1; SMN2 4746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.